[
  {
    "ts": null,
    "headline": "Is Pfizer Stock an Underrated Healthcare Investment Play?",
    "summary": "Pfizer is playing catch-up in the GLP-1 drug space, but the drugmaker has a long history of success.",
    "url": "https://finnhub.io/api/news?id=867d50ec02f9eeec157b977fa6208664d76f6e23196c030d38eda1889197a8e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771622400,
      "headline": "Is Pfizer Stock an Underrated Healthcare Investment Play?",
      "id": 139163792,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pfizer is playing catch-up in the GLP-1 drug space, but the drugmaker has a long history of success.",
      "url": "https://finnhub.io/api/news?id=867d50ec02f9eeec157b977fa6208664d76f6e23196c030d38eda1889197a8e4"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Stock Falls Despite Barclays Giving 'Overweight' Rating on Obesity Drugs",
    "summary": "Omvoh Shows Three-Year Efficacy in Crohn's Patients; Stock Reacts Modestly",
    "url": "https://finnhub.io/api/news?id=e89918a38c0e9693af027644e020e4d4a0dd82fbca2fdd70752458b705bb26e1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771620455,
      "headline": "Eli Lilly Stock Falls Despite Barclays Giving 'Overweight' Rating on Obesity Drugs",
      "id": 139163793,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Omvoh Shows Three-Year Efficacy in Crohn's Patients; Stock Reacts Modestly",
      "url": "https://finnhub.io/api/news?id=e89918a38c0e9693af027644e020e4d4a0dd82fbca2fdd70752458b705bb26e1"
    }
  },
  {
    "ts": null,
    "headline": "Barclays Initiates Coverage of Eli Lilly and (LLY) with Overweight Recommendation",
    "summary": "Barclays Initiates Coverage of Eli Lilly and (LLY) with Overweight Recommendation",
    "url": "https://finnhub.io/api/news?id=2925111fe7ae5021ff8fa404b927ea5fdbffc78545174b025fd2d63885303f61",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771617849,
      "headline": "Barclays Initiates Coverage of Eli Lilly and (LLY) with Overweight Recommendation",
      "id": 139163483,
      "image": "",
      "related": "LLY",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=2925111fe7ae5021ff8fa404b927ea5fdbffc78545174b025fd2d63885303f61"
    }
  },
  {
    "ts": null,
    "headline": "Forget Ozempic: This High‑Flying Device Maker Can Thrive No Matter Which Weight Loss Drug Wins",
    "summary": "Wall Street is overly focused on GLP-1 drugs even as this medical device maker continues to thrive.",
    "url": "https://finnhub.io/api/news?id=ecef285a904c2a893f6a9e37ac8d823ce4c5eecb17bc8adaaf6db1f1c8ede5c2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771612500,
      "headline": "Forget Ozempic: This High‑Flying Device Maker Can Thrive No Matter Which Weight Loss Drug Wins",
      "id": 139163183,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Wall Street is overly focused on GLP-1 drugs even as this medical device maker continues to thrive.",
      "url": "https://finnhub.io/api/news?id=ecef285a904c2a893f6a9e37ac8d823ce4c5eecb17bc8adaaf6db1f1c8ede5c2"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=3d464da7e39ee555aa4606f09475a187ee2f2c37da7d4c1303df766a67e1c928",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771596006,
      "headline": "Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 139162555,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=3d464da7e39ee555aa4606f09475a187ee2f2c37da7d4c1303df766a67e1c928"
    }
  },
  {
    "ts": null,
    "headline": "Will Immunology Drugs Continue to Drive AbbVie's Top Line in 2026?",
    "summary": "ABBV's Skyrizi and Rinvoq drove more than 40% growth in 2025. Can these immunology blockbusters power double-digit gains again in 2026?",
    "url": "https://finnhub.io/api/news?id=55bb5c683f136bfd7c7ffb84a2e303dee23e00d45768a77fa4d36b2803efe29e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771593360,
      "headline": "Will Immunology Drugs Continue to Drive AbbVie's Top Line in 2026?",
      "id": 139161260,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "ABBV's Skyrizi and Rinvoq drove more than 40% growth in 2025. Can these immunology blockbusters power double-digit gains again in 2026?",
      "url": "https://finnhub.io/api/news?id=55bb5c683f136bfd7c7ffb84a2e303dee23e00d45768a77fa4d36b2803efe29e"
    }
  },
  {
    "ts": null,
    "headline": "Barclays launches U.S. biopharma coverage with four preferred picks",
    "summary": "Investing.com -- Barclays launched coverage of U.S. large-cap biopharmaceutical companies, arguing the sector could regain investor attention in an uncertain macro backdrop, while naming Eli Lilly (NYSE:LLY), Merck (NYSE:MRK), Bristol-Myers Squibb (NYSE:BMY) and AbbVie Inc (NYSE:ABBV) as its top picks.",
    "url": "https://finnhub.io/api/news?id=24defe4374fd77db8c0683e041cc1dc376df6732125794a437ba7de5060bb531",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771592903,
      "headline": "Barclays launches U.S. biopharma coverage with four preferred picks",
      "id": 139159098,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- Barclays launched coverage of U.S. large-cap biopharmaceutical companies, arguing the sector could regain investor attention in an uncertain macro backdrop, while naming Eli Lilly (NYSE:LLY), Merck (NYSE:MRK), Bristol-Myers Squibb (NYSE:BMY) and AbbVie Inc (NYSE:ABBV) as its top picks.",
      "url": "https://finnhub.io/api/news?id=24defe4374fd77db8c0683e041cc1dc376df6732125794a437ba7de5060bb531"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk’s Wegovy® Pill Achieves Strong First-Month Uptake, Signaling Expanding Demand for Oral GLP-1s in Obesity",
    "summary": "Awareness and prescribing of the Wegovy pill for weight loss surge among primary care physicians and endocrinologists following its January launch.Exton, PA, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The obesity treatment landscape continues to evolve rapidly as demand for GLP-1–based therapies remains strong and competition intensifies. Novo Nordisk’s December 2025 FDA approval of Wegovy® (semaglutide), the first oral GLP-1 approved for chronic weight management, marked a pivotal expansion beyond injec",
    "url": "https://finnhub.io/api/news?id=388c2a448db15767aca06805f3ca0d31c4770387009dc3d400bcf29bba6ff8b4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771592280,
      "headline": "Novo Nordisk’s Wegovy® Pill Achieves Strong First-Month Uptake, Signaling Expanding Demand for Oral GLP-1s in Obesity",
      "id": 139159099,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Awareness and prescribing of the Wegovy pill for weight loss surge among primary care physicians and endocrinologists following its January launch.Exton, PA, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The obesity treatment landscape continues to evolve rapidly as demand for GLP-1–based therapies remains strong and competition intensifies. Novo Nordisk’s December 2025 FDA approval of Wegovy® (semaglutide), the first oral GLP-1 approved for chronic weight management, marked a pivotal expansion beyond injec",
      "url": "https://finnhub.io/api/news?id=388c2a448db15767aca06805f3ca0d31c4770387009dc3d400bcf29bba6ff8b4"
    }
  },
  {
    "ts": null,
    "headline": "Roche gets FDA decision date on closely watched breast cancer drug",
    "summary": "The agency could by late December approve a therapy that Roche sees as potentially becoming a new treatment standard for certain breast tumors.",
    "url": "https://finnhub.io/api/news?id=48eb357a4a0cf895e30e82b573f55db63a31545d4b6d0d57ab7cfeeffcd19bcd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771589782,
      "headline": "Roche gets FDA decision date on closely watched breast cancer drug",
      "id": 139162557,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The agency could by late December approve a therapy that Roche sees as potentially becoming a new treatment standard for certain breast tumors.",
      "url": "https://finnhub.io/api/news?id=48eb357a4a0cf895e30e82b573f55db63a31545d4b6d0d57ab7cfeeffcd19bcd"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Breaks New Ground In Crohn's Disease Treatment",
    "summary": "Eli Lilly (LLY) reports landmark Phase 3 data for Omvoh, showing over 90% of Crohn&#39;s disease patients achieved 3-year steroid-free remission.",
    "url": "https://finnhub.io/api/news?id=f54f88bb39a441bd6fbc8ba491843258e30910fdef6e7b4af40fc525353d46da",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771575831,
      "headline": "Eli Lilly Breaks New Ground In Crohn's Disease Treatment",
      "id": 139158803,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/20/Eli-Lilly.jpeg?width=2048&height=1536",
      "related": "LLY",
      "source": "Benzinga",
      "summary": "Eli Lilly (LLY) reports landmark Phase 3 data for Omvoh, showing over 90% of Crohn&#39;s disease patients achieved 3-year steroid-free remission.",
      "url": "https://finnhub.io/api/news?id=f54f88bb39a441bd6fbc8ba491843258e30910fdef6e7b4af40fc525353d46da"
    }
  },
  {
    "ts": null,
    "headline": "ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing",
    "summary": "Terns Pharmaceuticals has delivered a significant rally over the past year, lifting expectations around its clinical pipeline. The latest filing shifts attention to upcoming data and the company’s ability to support its valuation.",
    "url": "https://finnhub.io/api/news?id=fd983a5c51f84f15faccf030b19d43d3152decdfc4c91b0480a13d3a36ac9b69",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771564942,
      "headline": "ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing",
      "id": 139155412,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Terns Pharmaceuticals has delivered a significant rally over the past year, lifting expectations around its clinical pipeline. The latest filing shifts attention to upcoming data and the company’s ability to support its valuation.",
      "url": "https://finnhub.io/api/news?id=fd983a5c51f84f15faccf030b19d43d3152decdfc4c91b0480a13d3a36ac9b69"
    }
  },
  {
    "ts": null,
    "headline": "3 Market-Beating Stocks to Consider Right Now",
    "summary": "Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the legendary stocks that return 100 times your money.",
    "url": "https://finnhub.io/api/news?id=04e1c058cccf4ba5db98b71b66ce0fc1f421664ba6c2fa1a3f018725f7f944be",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771562618,
      "headline": "3 Market-Beating Stocks to Consider Right Now",
      "id": 139161565,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the legendary stocks that return 100 times your money.",
      "url": "https://finnhub.io/api/news?id=04e1c058cccf4ba5db98b71b66ce0fc1f421664ba6c2fa1a3f018725f7f944be"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Announces Positive Phase 3b Results for Taltz and Zepbound Combination Treatment in Psoriasis and Obesity",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy for the next 20 years. On February 18, Eli Lilly announced positive topline results from the Phase 3b TOGETHER-PsO trial, which found that using Taltz (ixekizumab) and Zepbound (tirzepatide) together provided superior results for adults with moderate-to-severe plaque psoriasis and obesity. […]",
    "url": "https://finnhub.io/api/news?id=2b844774f4de84387e56c2c2c4aa6149cdeb0171c675439efb0fb068ff62dfac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771547289,
      "headline": "Eli Lilly (LLY) Announces Positive Phase 3b Results for Taltz and Zepbound Combination Treatment in Psoriasis and Obesity",
      "id": 139153565,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy for the next 20 years. On February 18, Eli Lilly announced positive topline results from the Phase 3b TOGETHER-PsO trial, which found that using Taltz (ixekizumab) and Zepbound (tirzepatide) together provided superior results for adults with moderate-to-severe plaque psoriasis and obesity. […]",
      "url": "https://finnhub.io/api/news?id=2b844774f4de84387e56c2c2c4aa6149cdeb0171c675439efb0fb068ff62dfac"
    }
  }
]